Title

Streptococcus pyogenes M1T1 variants activate caspase-1 and induce an inflammatory neutrophil phenotype

Authors/Affiliations

Jonathan G. Williams[1,2], Diane Ly[1,2], Nicholas J. Geraghty[1,2], Jason D. McArthur[1,2], Heema K. N. Vyas[1,2], Jody Gorman[1,2], James A. Tsatsaronis[3], Ronald Sluyter[1,2], Martina L. Sanderson-Smith[1,2,4,*]

[1]Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia.

[2]Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, New South Wales, Australia.

[3]College of Science, Health and Engineering, La Trobe University, Bundoora, Victoria, Australia.

[4]Lead contact

Contact Info

*Correspondence: Illawarra Health and Medical Research Institute (IHMRI), School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia. E-mail: martina@uow.edu.au

Summary

Invasive infections due to Group A *Streptococcus* (GAS) advance rapidly causing tissue degradation and unregulated inflammation. Neutrophils are the primary immune cells that respond to GAS. The neutrophil response to GAS was characterised in response to two M1T1 isolates; 5448 and animal passaged variant 5448AP. Neutrophil co-incubation with 5448AP allowed proliferation of GAS while it also lowered the production of reactive oxygen species by neutrophils when compared with 5448. Infection with both strains invoked neutrophil death, however apoptosis was reduced in response to 5448AP. Both strains induced neutrophil caspase-

1 activation and caspase-4 expression *in vitro*, with caspase-1 activation detected *in vivo*. Thus, GAS infection of neutrophils corresponds to increased caspase-1 activity and caspase-4 expression, consistent with inflammasome activation and pyroptosis. GAS infections that promote an inflammatory neutrophil phenotype may contribute to increased inflammation yet ineffective bacterial eradication, contributing to the speed and severity of invasive GAS infections.

Keywords

Polymorphonuclear leukocyte, PMN, apoptosis, pyroptosis, caspase-1, caspase-3, caspase-4, CD16, CD31, CD66b, CD11b, IL-1β, TNF-α, IL-8, IL-18, cell-death, *covS*, 5448, 5448AP, LEGENDplex, FLICA, inflammation, inflammasome

Introduction

Invasive infections due to the obligate human pathogen *Streptococcus pyogenes* (Group A *Streptococcus*; GAS) are characterised by unregulated inflammation and high mortality (Davies et al., 1996, Lamagni et al., 2008, Nelson et al., 2016, O'Grady et al., 2007, O'Loughlin et al., 2007, Svensson et al., 2000). The highly virulent GAS M1T1 clone 5448 is well studied (Aziz and Kotb, 2008, Tart et al., 2007, Walker et al., 2007). The propensity of M1T1 GAS to cause invasive infections is due, in part, to the increased frequency of spontaneous mutations in the two-component control of virulence regulatory system (covRS) (Walker et al., 2007), resulting in differential expression of multiple virulence factors, many of which are implicated in immune defence (Kilsgård et al., 2016, Sumby et al., 2005, Sumby et al., 2006, Walker et al., 2007). Compelling evidence describes the resistance of *covS* mutant GAS (mutation to the sensor protein of covRS) to killing by human neutrophils (polymorphonuclear leukocytes, PMNs) (Ato et al., 2008, Maamary et al., 2010, Walker et al., 2007). 5448AP (animal passaged) is one M1T1 *covS* mutant strain that shows resistance to killing by human neutrophils, has increased bacterial dissemination and results in decreased survival in mouse models of infection (Fiebig et al., 2015,

48 Maamary et al., 2010, Walker et al., 2007). Due to these characteristics, 5448AP can be used as a
49 model strain to explore the host response to invasive GAS infection.

50 Neutrophils are the primary innate immune cell-type that defend against bacterial pathogens,
51 with their presence contributing to the overarching inflammatory response (Kobayashi et al.,
52 2018). Proteins of neutrophil origin are highly abundant at sites of invasive GAS infection
53 (Edwards et al., 2018). The neutrophil life cycle is tightly regulated to avoid the release of
54 cytotoxic contents that can damage surrounding tissue and contribute further to inflammation
55 (Epstein and Weiss, 1989, Faurschou and Borregaard, 2003). Under normal conditions cytotoxic
56 reactive oxygen species (ROS) produced by neutrophils kill phagocytosed bacteria (Nguyen et al.,
57 2017). An increased production of ROS signals for the induction of the anti-inflammatory cell-
58 death pathway apoptosis (Lundqvist-Gustafsson and Bengtsson, 1999). During apoptosis,
59 neutrophils are carefully decommissioned, ensuring no unregulated release of intracellular
60 material, then cleared by a secondary phagocyte, macrophages, through a process known as
61 efferocytosis (Bratton and Henson, 2011). The cleavage of caspase-3 to the p17 form denotes the
62 execution of apoptosis (Nicholson et al., 1995). Increased neutrophil apoptosis is described
63 during GAS infection (Kobayashi et al., 2003). Pro-inflammatory neutrophil death has also been
64 reported during GAS infection (Tsatsaronis et al., 2015). One form of pro-inflammatory death is
65 pyroptosis, involving the formation of an inflammasome and subsequent caspase-1 or caspase-4
66 activation, culminating in cell-lysis (Man and Kanneganti, 2016, Sollberger et al., 2012).
67 Deregulation of (or excessive) pro-inflammatory neutrophil-death may therefore contribute
68 further to inflammatory pathology, as demonstrated during infection with other pathogens,
69 including *Pseudomonas aeruginosa* (Ryu et al., 2017) and *Staphylococcus aureus* (Ghimire et al.,
70 2018, Greenlee-Wacker et al., 2017, Ryu et al., 2017). Inflammation is also heavily influenced by
71 cell cytokine production, where increased release can invoke neutrophil dysfunction, affecting
72 neutrophil survival, antibacterial function or even migration (Brown et al., 2006, Kipnis, 2013,
73 Kovach and Standiford, 2012, Norrby-Teglund et al., 2000). Previous work outlines how GAS take
74 advantage of inadequate or exacerbated immune responses and focus upon the bacterial

75 mechanisms involved (Cole et al., 2011). Although models to investigate leukocyte inflammasome
76 activation have been proposed (Tran et al., 2019), a limited number of studies have investigated
77 the neutrophil response to GAS specifically (Kobayashi et al., 2003). Here, using an *in vitro* model,
78 we temporally describe the effect two M1T1 GAS strains have upon human neutrophil death,
79 signalling and inflammatory profile. We further characterise this interaction in murine
80 neutrophils, using an *in vivo* model of intradermal invasive GAS infection. Additionally, we
81 identify differences in the neutrophil response to GAS due to *covS* mutation. We hypothesise that
82 changes to neutrophil function by GAS can promote invasive GAS infection by exacerbating the
83 inflammatory response, decreasing antibacterial capacity and inducing inflammatory neutrophil
84 death.

85 **Results**

86 **GAS persistence and proliferation occurs during a dampened neutrophil ROS response**

87 Neutrophil phagocytic ability is a predominant and well-established mechanism of immune
88 defence. Both GAS strains 5448 and 5448AP rapidly associated with human neutrophils, with
89 near maximal association observed within 30 min (Figures 1A and S1A-C). Higher percentages of
90 neutrophils were associated with 5448 compared to 5448AP (Figure 1A). 5448 and 5448AP also
91 induced ROS production in neutrophils, with less ROS produced by neutrophils incubated in the
92 presence and absence of 5448AP compared to those incubated with 5448 (Figure 1B). As such,
93 the rate of neutrophil ROS production was significantly increased compared to the neutrophil
94 only control during 5448, but not 5448AP, infection ($p<0.01$, Figure S1D), suggesting dampened
95 antibacterial function in neutrophils in response to 5448AP. This difference in GAS-induced ROS
96 production inversely corresponded to GAS proliferation in the presence of neutrophils, with high
97 numbers of 5448AP observed compared to 5448 over 180 min (Figure 1C). Differential GAS
98 proliferation required viable neutrophils, as 5448 and 5448AP proliferation in the presence of
99 neutrophil lysates was reduced and similar for both strains over 180 min (Figure 1D). Finally,
100 incubation of neutrophils with the phagocytosis inhibitor cytochalasin D significantly increased

101 5448, but not 5448AP, survival (p<0.001, Figure S1E), indicating that 5448 killing is
102 predominantly mediated via a phagocytic-related pathway. Collectively, these data indicate that
103 compared to 5448, 5448AP associates less readily with human neutrophils leading to reduced
104 ROS production and increased survival of this strain.



105 **Figure 1. GAS persistence and proliferation occurs during a dampened neutrophil ROS**
106 **response.** (A) Association of fluorescent GAS strains with human neutrophils (PMNs, n=6
107 donors), analysed via flow cytometry (Figure S1A-B). (B) Infection of human neutrophils with
108 GAS invokes ROS production. Representative of triplicate measurements from three separate
109 experiments (n=3 donors), shown as mean change in fluorescence units over time ($\Delta F.min^{-1}$). GAS
110 strains were incubated in the presence of (C) human neutrophils (n=8 donors) or (D) lysed
111 human neutrophils (n=4 donors) over 180 min with surviving bacterial concentration
112 determined as percentage of inoculum. Results are the pooled means±SD (of triplicate
113 measurements for panels C and D). **p<0.01 and ****p<0.0001.

114 **Neutrophil death is delayed during infection with 5448AP**

115 GAS can induce death of human neutrophils (Kobayashi et al., 2003, Tsatsaronis et al., 2015),
116 however the mechanism remains poorly described. Phosphatidylserine (PS) exposure is a

117 hallmark of the induction of multiple death pathways including apoptosis and pyroptosis (Man
118 and Kanneganti, 2016, Wang et al., 2013). Human neutrophils were incubated with 5448, 5448AP
119 or in the absence of GAS then the binding of annexin-V (AV), as a measure of PS exposure, and the
120 binding of Zombie Fixable Viability Kit (Z), as a measure of membrane integrity, were analysed
121 by flow cytometry (Figure 2). Cells were defined as viable ($AV_{-}Z_{-}$), PS exposed ($AV_{+}Z_{-}$) or dead
122 ($AV_{+}Z_{+}$) (Figure 2C). Neutrophils incubated without GAS remained viable over 180 min (Figure
123 2D), with 13% exposing PS (Figure 2E) and 3% dead after this time (Figure 2F). In contrast,
124 incubation of neutrophils with either 5448 or 5448AP resulted in increased PS exposure and cell-
125 death over 180 min, with significantly more cell-death during 5448 infection compared to
126 5448AP infection at 30 and 60 min ($p<0.05$, Figure 2F). Delay in the initial induction of death in
127 response to 5448AP suggests extended neutrophil viability during the early stages of infection
128 (30-60 min).

129 **GAS infection activates caspase-1 in neutrophils**

130 The above data (Figure 2) suggests that GAS induce rapid neutrophil death. To explore the
131 mechanism of GAS-induced neutrophil death human neutrophil lysates were separated by SDS-
132 PAGE and screened for the abundance of active caspase-3, caspase-1 and caspase-4 via
133 immunoblotting and quantified using densitometry (Figures 3A and S2A-D). Cleavage of
134 executioner caspase-3 to p17 is a definitive hallmark of apoptosis induction (Nicholson et al.,
135 1995). Conversely, caspase-1 and caspase-4 activity can indicate inflammasome activation, which
136 in turn can cleave downstream effectors of pyroptosis (Man and Kanneganti, 2016, Sollberger et
137 al., 2012). Moreover, a recent report has identified the caspase-1 p46 molecule as the principal
138 active species during inflammasome activation in the cell (Boucher et al., 2018). Neutrophils
139 incubated in the absence of GAS showed limited evidence of caspase-3 cleavage to p17 (Figures
140 3A and S2A), while levels of caspase-1 reduced over 180 min (Figures 3A and S2B-C). Infection of
141 neutrophils with 5448 significantly increased the presence of caspase-3 p17 at 180 min
142 ($p>0.0001$) compared to both 5448AP-infected and uninfected neutrophils (Figures 3A and S2A).

143 In contrast, incubation of neutrophils with either GAS strain caused an upregulation of caspase-1
144 (Figures 3A and S2B-C). Compared to uninfected neutrophils, 5448 infection significantly
145 increased pro-caspase-1 (50kDa) at 30 min, 60 min ($p<0.05$) and 180 min ($p<0.01$), whilst
146 5448AP infection only significantly increased pro-caspase-1 at 180 min ($p<0.001$, Figures 3A and
147 S2B). Further, 5448 and 5448AP infected neutrophils sustain p46 expression over 180 min,
148 though this difference was not statistically significant (Figure 3A and S2C). Significant differences
149 were not seen in the expression of caspase-1 between 5448 and 5448AP infected neutrophils.
150 Similar to caspase-1, the abundance of full-length caspase-4 in neutrophils incubated in the
151 absence of GAS declined over time (Figures 3A and S2D). In contrast, 5448 infection increased
152 caspase-4 expression at 30 ($p<0.01$), 60 ($p<0.001$) and 180 min compared to uninfected
153 neutrophils ($p<0.0001$, Figures 2A and S2D). 5448AP infection however, only increased caspase-
154 4 expression at 180 min ($p<0.01$, Figures 3A and S2D).

155 The above data suggest both GAS strains induce pyroptosis in neutrophils, but the response to
156 5448AP is delayed. To explore this possibility further, human neutrophils were incubated with
157 5448, 5448AP or in the absence of GAS, and caspase-1 activity assessed using a fluorogenic flow
158 cytometric caspase-1 assay (Figures 3B and S3A-C). 5448 infected neutrophils showed increased
159 active caspase-1 at 60 min and 180 min ($p<0.05$), whilst 5448AP infection increased caspase-1 at
160 180 min ($p<0.05$) compared to uninfected neutrophils (Figure 3B). No significant differences
161 were observed between strains although caspase-1 activity was slightly reduced during 5448AP
162 infection compared to 5448 (Figure 3B), similar to the immunoblot data for caspase-1 p46
163 (Figures 3A and S2C). Thus, GAS infection of human neutrophils corresponds to increased
164 caspase-1 activity and caspase-4 expression, consistent with inflammasome activation and
165 pyroptosis.



Figure 2. GAS infection induced neutrophil death. Human neutrophils (PMNs) were stained with Annexin V-FITC and Zombie Aqua Fixable Viability Kit via flow cytometry and initially gated upon (A) 'Singlets' (FSC-A vs. FSC-H, 10,000 events collected). 'All PMNs' (live and dead) were selected using (B) a gate excluding GAS. Cells were then compared for fluorescence of (C) annexin V-FITC/phosphatidylserine (PS) binding against Zombie live/dead viability dye. Purified PMNs were sampled over 180 min to measure (D) 'Viable' ($AV_{-}Z_{-}$), (E) 'PS exposed' ($AV_{+}Z_{-}$), and (F) 'Dead' ($AV_{+}Z_{+}$), neutrophils during GAS infection (n=3 donors). Results are pooled means±SD . *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, with black asterisks denoting significance from control and grey asterisks between 5448 and 5448AP.

Proinflammatory cytokines IL-1β and TNF-α are released by neutrophils in response to GAS infection

The release of the inflammatory cytokine IL-1β occurs due to caspase-1 activation and is associated with the induction of pyroptosis (Broz et al., 2010). Uncoordinated release of various inflammatory cytokines can exacerbate infection (Tecchio et al., 2014). During GAS infection,

180 disease severity is negatively correlated to cytokine concentration (Norrby-Teglund et al., 2000).
181 Therefore, human neutrophils were incubated with 5448, 5448AP or in the absence of GAS and
182 supernatants assessed for cytokines using a flow cytometric bead assay. Neutrophils incubated
183 in the absence of GAS failed to release IL-1β (Figure 3C) and TNF-α (Figure 3D) despite releasing
184 increasing amounts of IL-8 over 360 min (Figure 3E). Incubation with GAS induced IL-1β release
185 from neutrophils at 180 min and 360 min, with significantly greater release during 5448AP
186 infection compared to 5448 at 180 and 360 min ($p<0.05$, $p<0.0001$, Figure 3C). Incubation with
187 GAS also induced significant release of TNF-α from neutrophils at 180 min ($p<0.001$) and 360 min
188 ($p<0.0001$), with significantly greater release during 5448 infection compared to 5448AP at 360
189 min ($p<0.0001$, Figure 3D). Compared to uninfected neutrophils, 5448 induced significant release
190 of IL-8 from neutrophils at 60 min and 180 min ($p<0.05$), with significantly greater release than
191 5448AP at 60 min ($p<0.05$, Figure 3E). Neutrophils released minimal amounts of IL-18 over 360
192 min, and this response did not change following infection with both 5448 or 5448AP (Figure 3F),
193 suggesting that neutrophils have no major role in IL-18 release over 360 min *in vitro*. These data
194 indicate that both 5448 and 5448AP induce IL-1β release from human neutrophils, consistent
195 with the hypothesis that both GAS strains induce pyroptosis in these cells. Moreover, the results
196 indicate differential cytokine release from human neutrophils infected with GAS, with 5448AP
197 inducing greater IL-1β release and 5448 inducing greater TNF-α and IL-8 release.



Figure 3. GAS infection activates caspase-1 in human neutrophils and induces proinflammatory cytokine IL-1β and TNF-α release. (A) Human neutrophil (PMN) lysates were prepared at 30, 60 and 180 min during GAS infection and compared to uninfected neutrophils (0, 30, 60, 180 min) via immunoblotting of caspase-3, caspase-1 and caspase-4. Images shown are from a single donor and are representative of triplicate experiments using different donors. Immunoblot bands were quantified (ImageJ) and normalised over total protein (Figure S2). SE=short exposure, LE=long exposure. (B) Caspase-1 activation in human neutrophils due to GAS infection was confirmed via flow cytometry using FLICA (FAM-YVAD-FMK) (n=3 donors). Flow cytometry gating strategy used singlets/PMNs (figure S3A-B) and FAM-FLICA fluorescence (Figure S3C). The release of cytokines from neutrophils during GAS infection was measured using the LEGENDplex™ human inflammation cytometric bead assay over 360 min. Neutrophils differentially released (C) IL-1β, (D) TNF-α, (E) IL-8 and (F) IL-18 in response to GAS

210 infection (duplicate measurements, n=6 donors). (B-F) Results are the pooled means±SD.
211 *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.

212 **GAS infection may cause neutrophil dysfunction**

213 Neutrophil adhesion and activation are central to the innate immune response, with CD11b (Mac-
214 1) and CD66b (CEACAM8) playing key respective roles (Arnaout, 1990, Power et al., 2001, Skubitz
215 et al., 1996). CD16 (FcγRIII) facilitates opsonisation of pathogens and is down-regulated during
216 apoptosis (Dransfield et al., 1994, Fossati et al., 2002), whilst down-regulation of CD31 (PECAM-
217 1) facilitates clearance of apoptotic neutrophils and the resolution of inflammation (Brown et al.,
218 2002, Kurosaka et al., 2003). Therefore, to further explore the impact of GAS on neutrophil
219 function, human neutrophils were incubated with 5448, 5448AP or in the absence of GAS and the
220 expression of cell-surface CD11b, CD66b, CD16 and CD31 was assessed using flow cytometry
221 (Figure 4A-F). In the absence of GAS, neutrophils displayed minor increases in CD11b expression
222 over time, while incubation with GAS resulted in minor decreases over time, with 5448 inducing
223 a greater loss of CD11b than 5448AP, though these differences were not statistically significant
224 (p=0.289, Figure 4C). Neutrophils incubated in the absence of GAS revealed minor increases in
225 cell-surface CD66b expression over time (Figure 4D). Incubation with GAS further increased
226 expression of CD66b, with 5448 inducing a slightly greater increase than 5448AP, though these
227 differences were not statistically significant (p=0.162, Figure 4D). Incubation of neutrophils in
228 the absence of GAS resulted in a steady decline in CD16 expression over time, a loss significantly
229 increased by co-incubation with either GAS strain 180 min post-infection (p<0.0001, Figure 4E).
230 Notably, incubation of neutrophils with 5448 induced a significantly greater loss of CD16
231 expression than 5448AP incubation at all earlier time points (Figure 4E). Similar to CD16,
232 incubation of neutrophils in the absence of GAS resulted in a steady decline in CD31 expression
233 over time, a loss significantly increased by co-incubation with either GAS strain 180 min post-
234 infection (p<0.0001, Figure 4F). Moreover, incubation of neutrophils with 5448 induced a
235 significantly greater loss of CD31 expression than 5448AP incubation at earlier time points.

236 Collectively, these data indicate that GAS has minimal impact upon human neutrophil CD11b and
237 CD66b, but increases the loss of CD16 and CD31 expression, which may impact opsonisation of
238 GAS and subsequent efferocytosis of neutrophils by macrophages, during infection.



239 **Figure 4. GAS infection changes neutrophil functionality.** Human neutrophils (PMNs) were
240 analysed using flow cytometry, sequentially gated upon (A) 'Singlets' (FSC-A vs. FSC-H, 10,000
241 events collected) then (B) viable 'PMNs' (FSC-A vs. FSC-H). Purified neutrophils infected with GAS
242 were sampled over 180 min for the cell-surface expression of (C) CD11b-FITC (n=4 donors), (D)
243 CD66b-PerCP/Cy5.5 (n=5 donors), (E) CD16-FITC (n=4 donors) and (F) CD31-PE/Cy7 (n=4
244 donors). Results are the pooled means±SD. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, with
245 black asterisks denoting significance from control and grey asterisks between 5448 and 5448AP.

246 **GAS infection activates caspase-1 in neutrophils *in vivo***

247 The above data indicate that GAS influences human neutrophils *in vitro.* To explore if GAS may
248 alter neutrophils *in vivo*, we assessed the neutrophil response in a mouse model of GAS infection
249 (Ly et al., 2014, Maamary et al., 2010, Tsatsaronis et al., 2014). C57BL/6J mice were injected
250 intradermally with 5448, 5448AP or saline and euthanised at 6 or 24 hours post infection, with
251 neutrophil populations ($CD45_+/CD11b_+/Ly\text{-}6G_+$), caspase-1 activation and CD16 expression

252 characterised by flow cytometry (Figures 5A-C, 5E and S4A-F). Infection of mice with either GAS
253 strain significantly increased neutrophil populations at sites of injection at both 6 and 24 h
254 compared to saline control ($p<0.001$, Figure 5A). The percentage of circulating neutrophils in the
255 blood at 6 h significantly increased during infection with both GAS strains ($p<0.01$), though the
256 response to 5448AP was significantly greater than 5448 ($p<0.05$, Figure 5B). Blood neutrophil
257 populations returned to baseline after 24 h, indicating the importance of neutrophils during the
258 early stages of infection (Figure 5B). Murine neutrophils lavaged from sites of saline injection had
259 low amounts of active caspase-1 (Figure 5B). Infection with 5448AP, but not 5448, significantly
260 increased caspase-1 activation at 6 h ($p<0.05$), while both strains increased caspase-1 activation
261 at 24 h ($p<0.001$, Figure 5C). Cytokines were assessed in murine serum using a flow cytometric
262 bead assay. IL-1β concentrations remained low for saline control and 5448 infected mice but
263 were significantly increased at 24 h during 5448AP infection ($p<0.0001$, Figure 5D). Neutrophils
264 lavaged from the site of saline and GAS injection displayed CD16 expression, with CD16
265 expression significantly increased due to 5448 but not 5448AP infection at 6 h when compared
266 to saline control ($p<0.05$, Figure 5E). The expression of CD16 on neutrophils from mice infected
267 with 5448 significantly decreased between 6 and 24 h ($p<0.01$), but no significant differences
268 were noted between times for either saline or 5448AP groups (Figure 5E).

269 **Discussion**

270 Here we have mapped the human neutrophil response to GAS, addressing cell-death, signalling
271 and the inflammatory profile during the early stages of M1T1 (5448 and 5448AP) infection, while
272 also confirming *in vitro* findings in a murine intradermal GAS infection model. For the first time,
273 we describe an inflammatory neutrophil phenotype, as evidenced by caspase-1 activation *in vitro*
274 and *in vivo*, that may promote inflammation and exacerbate GAS disease. Most notably, changes
275 to the expression of cell-surface proteins CD16 and CD31 may impede the removal of bacteria and
276 clearance of neutrophils at sites of infection, hindering the resolution of inflammation. Further,

277 we elucidate differences between 5448 and 5448AP that aid in understanding the survival and

278 proliferation of GAS harbouring *covS* mutations in the presence of human neutrophils.



279 **Figure 5. GAS infection *in vivo* activates caspase-1 in murine neutrophils.** Percentage of

280 CD45+ cells (A) lavaged from site of injection and in (B) circulating blood characterised as

281 neutrophils (PMNs, CD11b+/Ly-6G+) by flow cytometry (Figure S4A-E). (C) Caspase-1 activation

282 in neutrophils at site of GAS infection was confirmed via flow cytometry using FLICA 660 (660-

283 YVAD-FMK, Figure S4F). Each data point represents the results from a single mouse where n=8.

284 (D) The release of IL-1β in mouse serum during GAS infection was measured using the

285 LEGENDplex™ mouse inflammation cytometric bead assay at 6 and 24 h post infection where

286 duplicate measurements are shown and n=8. (E) CD16 expression of PMNs lavaged from the site

287 of injection and determined using flow cytometry. Each data point represents the results from a

288 single mouse where n=8. Results are the means±SD. *p<0.05, **p<0.01, ***p<0.001 and

289 ****p<0.0001, with black asterisks denoting significance from control and grey asterisks between

290 5448 and 5448AP, or as indicated by a line.

291 The temporal expression of neutrophil cell surface markers has not previously been investigated
292 in the context of GAS infection. Our data show that significant reductions to both CD16 and CD31
293 occur in neutrophils due to GAS infection *in vitro*. Additionally, *in vivo* data indicates that a
294 reduction in CD16 expression is seen during 5448 infection between 6 and 24 h. CD16 functions
295 as a receptor for opsonised bacteria and immune complexes (Fossati et al., 2002), whilst the loss
296 of CD16 has also been associated with the induction of apoptosis (Dransfield et al., 1994). The
297 induction of apoptosis following bacterial phagocytosis is advantageous to the host as it promotes
298 controlled removal of bacteria and the resolution of inflammation (Kobayashi et al., 2018). We
299 hypothesise that the retention of CD16 during infection promotes a reduction in apoptosis and
300 prolonged degranulation at the site of infection. Further, CD31 expression is reduced during GAS
301 infection, facilitating the eventual removal of neutrophils from sites of infection (Kobayashi et al.,
302 2003). Parallel to CD16, CD31 is retained during 5448AP infection of neutrophils to a greater
303 extent than 5448 infection *in vitro*. This may result in neutrophils remaining at sites of infection
304 longer, further increasing inflammation. Additionally, we report a trend towards increased cell-
305 surface expression of CD11b and CD66b during GAS infection. Migration of neutrophils to sites of
306 infection, facilitated by CD11b-mediated neutrophil adhesion (Arnaout, 1990), may therefore be
307 affected during GAS infection. Down-regulation of CD11b can prevent accumulation of
308 neutrophils at inflammatory sites (Huston et al., 2009), however retention, such as that seen
309 during 5448AP infection may contribute to prolonged inflammation. Neutrophil activation can be
310 determined through the expression of cell-surface CD66b following stimulation (Skubitz et al.,
311 1996). Reduced cell-surface CD66b expression in response to 5448AP infection may therefore
312 indicate a reduction to neutrophil function and further explain the resistance to neutrophil-
313 mediated killing. Collectively, the neutrophil response is altered and inflammation prolonged at
314 sites of *covS* mutant GAS infection.

315 Disruption of the role neutrophils play during the resolution of GAS infection and induction of
316 inflammatory death pathways has been reported previously (Kobayashi et al., 2003, Tsatsaronis
317 et al., 2015). Proinflammatory activation of the NLRP3 inflammasome in macrophages has been

318 demonstrated for M1 GAS (Valderrama et al., 2017), here we provide the first evidence that GAS
319 activates caspase-1 in human and murine neutrophils, consistent with inflammasome activation
320 and pyroptosis. Caspase-1 activation was consistent during infection with both M1T1 GAS
321 isolates, however the release of inflammatory cytokine IL-1β, a hallmark of clinical invasive
322 infection (LaRock and Nizet, 2015), was only significantly increased in response to 5448AP
323 infection *in vitro* and *in vivo*. In murine bone marrow-derived dendritic cells caspase-1 activation
324 is essential for IL-1β release (Schneider et al., 2017). The activation of caspase-1 in human and
325 murine neutrophils does not correlate directly to the amount of IL-1β released, and an alternative
326 mechanism may facilitate IL-1β maturation. Type I interferons are known regulators of IL-1β in
327 GAS infected mice (Castiglia et al., 2016), where increased IL-1β release in murine serum seen in
328 this study may also be attributed to disruption of this homeostatic relationship. Increased IL-1β,
329 being a neutrophil chemoattractant, therefore may further promote inflammation at sites of
330 infection following release (Chen et al., 2007), supporting the hypothesis that *covS* mutant GAS
331 promote greater levels of inflammation during GAS infection.

332 Previous studies have characterised differences between 5448 and 5448AP, demonstrating
333 resistance to neutrophil-mediated killing *in vitro* and increased bacterial dissemination and
334 decreased survival *in vivo* following the acquisition of *covS* mutations (Fiebig et al., 2015,
335 Maamary et al., 2010, Walker et al., 2007). Here, we demonstrate that 5448AP is not only resistant
336 to neutrophil-mediated killing but proliferates in the presence of functional neutrophils. GAS
337 survival has been demonstrated intracellularly in murine neutrophils and human macrophages
338 (Medina et al., 2003a, Medina et al., 2003b, O'Neill et al., 2016) and can even be facilitated by host
339 red blood cells (Wierzbicki et al., 2019). Increased 5448AP proliferation may result from the
340 reduction in neutrophil ROS response during infection. GAS has previously been shown to display
341 resistance to ROS through numerous virulence mechanisms (Henningham et al., 2015). The
342 absence of a hostile environment may further permit bacterial replication. Additionally, the
343 increased production of ROS can induce neutrophil death via apoptosis (Geering and Simon,
344 2011). Reduced neutrophil ROS production during 5448AP infection may therefore explain the

345 reduction seen in caspase-3 activation (apoptosis). Previously it has been demonstrated that GAS
346 M1 strain MGAS5005 modulates neutrophil apoptosis (Kobayashi et al., 2003), a finding which is
347 supported by the current study.

348 Changes to the function of neutrophils during the initial innate immune response have the
349 potential to hinder mechanisms essential for the resolution of infection. Disruption to these
350 processes during GAS infection may induce this neutrophil phenotype we have described, with
351 increased inflammatory properties and potential to exacerbate infection. Caspase-1 activation
352 during GAS infection of neutrophils indicates possible inflammasome activation and death via
353 pyroptosis. Further studies should explore the precise cell death mechanism. A reduction in
354 apoptosis is evident during *covS* GAS infection, as has been reported for non-M1T1 GAS
355 (Tsatsaronis et al., 2015), whilst modulation of apoptosis has previously been implicated as a
356 factor contributing to GAS survival (Kobayashi et al., 2003). The current study aids in
357 understanding the complex host-pathogen interaction identifying host factors that may
358 contribute to severe pathology of invasive GAS infection. Future studies may be able to isolate
359 host-specific targets that could be exploited to control inflammation and tissue damage during
360 invasive GAS infection.

361 **Acknowledgements**

362 We thank Professor Marijka Batterham (University of Wollongong) for her statistical
363 consultation. We thank Associate Professor Thomas Proft (University of Auckland, New Zealand)
364 for pLZ12Km2-P23R:TA. We also thank our generous blood donors for their participation and
365 time.

366 **Author Contributions**

367 Conceptualisation, M.S.S, R.S., J.A.T., J.G.W.; Methodology, M.S.S., R.S., J.G.W., J.G., J.D.M., D.L.;
368 Investigation, J.G.W., D.L., N.J.G., H.K.N.V.; Data and figure curation, J.G.W., D.L., R.S., M.S.S.; Writing-
369 Original draft, J.G.W.; Writing-Review and editing, M.S.S., R.S., J.G.W., D.L., N.J.G., J.D.M., H.K.N.V.,

370 J.G., J.A.T.; Funding acquisition, M.S.S and D.L.; Resources, M.S.S., J.D.M.; Supervision, M.S.S., R.S.,
371 J.G.

372 **Declaration of Interests**

373 The authors declare no competing interests.

374 **Materials and Methods**

375 **Ethics statement**

376 All experiments involving the use of human blood were conducted with informed consent of
377 healthy volunteers, approved and authorised by the University of Wollongong Human Research
378 Ethics Committee (Protocol HE08/250). All experiments involving the use of animals were
379 approved and authorised by the University of Wollongong Animal Ethics Committee (Protocol
380 AE18/10).

381 **Bacterial strains and culture**

382 *Escherichia coli* MC106 were grown in Luria–Bertani Broth (LB) at 37 °C with constant shaking.
383 M1T1 *S. pyogenes* invasive clinical isolate 5448 (*emm1*) and hypervirulent animal passaged
384 5448AP (containing a non-functional control of virulence regulator mutation) have been
385 described previously (Aziz et al., 2004, Chatellier et al., 2000). GAS strains were routinely cultured
386 at 37°C on horse-blood agar (Thermo Fisher) and enumerated on yeast supplemented (1% w/v)
387 Todd-Hewitt (THY, Benton Dickson) agar. Static overnight cultures were grown at 37°C in THY
388 then sub-inoculated (1:10) into fresh THY and grown to mid-logarithmic phase, antibiotics were
389 added when required (100 µg/ml ampicillin and 200 µg/ml kanamycin). Bacterial pellets were
390 washed twice with phosphate buffered saline (PBS) then resuspended at the specified
391 multiplicity of infection (MOI) and assay specific media conditions.

392 **Construction of GFP expression vector pLZ12Km2-P23R-TA:GFP for GAS**

393 In brief, stable GFP expression by GAS was created by synthesizing the ribosomal binding site
394 (RBS) and *gfp* gene from pDC*erm*-GFP (Ly et al., 2014) into the pUC57 plasmid (GenScript),
395 resulting in pUC57-RBSGFP plasmid. RBS and *gfp* from pUC57-RBSGFP were then sub-cloned
396 using NotI into the toxin–antitoxin (TA) stabilized expression plasmid pLZ12Km2-P23R:TA,
397 kindly provided by Associate Professor Thomas Proft (University of Auckland, New Zealand) (Loh
398 and Proft, 2013), to produce pLZ12Km2-P23R-TA:GFP. The resultant plasmid system utilises the
399 *Streptococcal* ω–ε–ζ TA cassette to achieve segregational plasmid stability under non-selective
400 conditions (Lioy et al., 2010).

401 Specifically, plasmids pLZ12Km2-P23R:TA and pUC57-RBSGFP (engineered with RBS and *gfp*
402 from pDC*erm*-GFP) were first transformed into chemically competent *E. coli* MC106 via
403 electroporation. The plasmids were then retrieved and purified from *E. coli* cultures using a
404 Wizard® Plus SV Minipreps DNA Purification System (Promega). The pLZ12Km2-P23R:TA
405 plasmid was digested with 20 U NotI enzyme and further treated with 5 U shrimp alkaline
406 phosphatase. The pUC57-RBSGFP plasmid was also incubated with 20 U NotI to excise the RBS
407 and *gfp* gene from pUC57-RBSGFP, and these were then ligated into digested pLZ12km2-P23R:TA
408 plasmid. The resulting plasmid, pLZ12Km2-P23R-TA:GFP, was then transformed and cloned in
409 MC106 *E. coli*, and later extracted and purified. pLZ12Km2-P23R-TA:GFP was transformed into
410 GAS using standard GAS electroporation techniques (McLaughlin and Ferretti, 1995).
411 Transformed GAS was confirmed for GFP expression via flow cytometry.

412 **Isolation of human neutrophils**

413 Venous human blood was drawn into 10 mL lithium heparin-coated Vacutainer (Benton Dickson)
414 tubes and layered over equal volumes of Polymorphprep (Axis Shield) and centrifuged as per
415 manufacturer's instructions. The resulting layer of neutrophils was isolated and erythrocytes
416 hypotonically lysed. Isotonic concentration was restored with Hank's Balanced Salt solution
417 (without Ca^{2+} or Mg^{2+}, Corning Inc.). Prior to experimentation neutrophils were resuspended at
418 specified concentrations in complete medium, Roswell Park Memorial Institute (RPMI)-1640

419 medium (Life Technologies) containing 2% heat-inactivated autologous plasma and 2 mM L-
420 glutamine (Life Technologies), unless otherwise stated. Neutrophil viability was assessed via
421 Trypan Blue (Sigma-Aldrich) staining and neutrophil purity was assessed using a Benton Dickson
422 LSR Fortessa X-20 flow cytometer via distinct forward and side scatter profiles or CD66b-
423 peridinin chlorophyll protein (PerCP)/Cy5.5 (clone G10F5, BioLegend) expression. Neutrophils
424 were maintained at room temperature throughout processing.

425 ***In vitro* infection of neutrophils with GAS**

426 Purified human neutrophils were seeded in either 96-well plates at MOI (GAS:neutrophil) 1:10
427 (survival and proliferation) or 10:1 (ROS production and cytokine release), 24-well plates at 10:1
428 (phagocytosis, Annexin-V/Viability staining, CD expression and FAM-FLICA caspase-1 activation)
429 or 6-well plates at 10:1 (immunoblotting) and incubated at 37°C in 5% CO_2.

430 **GAS survival and proliferation**

431 Human neutrophils were co-cultured with GAS or lysed via three freeze-thaw cycles prior to
432 incubation. To block phagocytosis neutrophils were preincubated with 10 μM cytochalasin D
433 (Cayman Chemicals) in complete medium at 37°C for 30 min prior to infection. At indicated time
434 points neutrophils were hypotonically lysed and surviving bacteria serially diluted before plating
435 on THY agar.

436 **GAS phagocytosis**

437 Human neutrophils were co-cultured with GAS expressing GFP for the times indicated in
438 complete medium. Cells were removed and washed twice with 10% (v/v) heat-inactivated foetal
439 bovine serum (FBS, Bovogen Biologicals) diluted in PBS, followed by data acquisition via flow
440 cytometry.

441 **ROS production**

442 ROS production was assessed as previously described (Kobayashi et al., 2003). Briefly, prior to
443 infection, human neutrophils were incubated in complete medium containing 25 μM
444 dichlorofluorescein (DCF, Molecular Probes) for 45 min at room temperature (RT). ROS
445 production was measured fluorometrically ($_{ex}$485 nm $_{em}$520 nm) using a POLARstar Omega plate
446 reader (BMG Labtech).

447 **Flow cytometry**

448 For human neutrophil in vitro assays, flow cytometry data was acquired using a BD LSR Fortessa
449 X-20 with excitation lasers; violet (405 nm), blue (488 nm), yellow/green (561 nm) and red (640
450 nm). Bandpass filters for Zombie Aqua Fixable Viability Kit (525/50), fluorescein isothiocynate
451 (FITC)/GFP/FAM FLICA (525/50), PerCP-Cy5.5 (695/40) R-phycoerythrin (PE, 586/15),
452 propidium iodide (PI, 610/20), PE-Cy7 (780/60) and allophycocyanin (APC, 670/30) were used.
453 For murine infection studies, flow cytometry data was acquired using an Invitrogen Attune NxT
454 with excitation lasers; violet (405 nm), blue (488 nm), yellow (561 nm) and red (638 nm).
455 Bandpass filters VL1 (440/50), VL2 (512/25), BL1 (530/30), YL1 (585/16), YL3 (695/40) and
456 RL2 (720/30) were used. Data was analysed using FlowJo software V10.6.1 (TreeStar Inc.).

457 **Annexin-V/viability staining**

458 To assess cell viability human neutrophils at indicated times were washed with PBS and
459 incubated with Zombie Aqua Fixable Viability Kit (BioLegend) for 15 min at RT. Cells were
460 washed again once with PBS, then 10% (v/v) FBS in PBS and stained with Annexin-V-FTIC
461 (BioLegend) for 15 min at RT. Cells were analysed immediately via flow cytometry.

462 **Immunoblotting and antibodies**

463 Following co-culture in the presence or absence of GAS, human neutrophil lysates were prepared
464 in RIPA buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, 1.0% (v/v) Triton X-100, 0.1% (w/v) SDS,
465 0.5% (w/v) sodium deoxycholate, 2x cOmplete protease inhibitor cocktail (Roche), 1 mM
466 phenylmethylsulphonyl fluoride, 5 mM sodium pyrophosphate, 5 mM sodium molybdate and 5

467 mM β-glycerophosphate) following co-culture in the presence or absence of GAS and incubated
468 for 30 min on ice with intermittent vortexing. Soluble fractions were separated via centrifugation
469 at 4°C, snap frozen in liquid N_2 and stored at -80°C. Protein concentrations were determined by
470 comparison to bovine serum albumin standards using the DC Protein Assay (Bio-Rad) and
471 absorbance (A_{750nm}) measured using a POLARstar Omega plate reader. Neutrophil lysates (20 µg)
472 were separated on 4-20% TGX Stain-Free protein gels (Bio-Rad) as per the manufacturer's
473 running conditions then activated for 5 min under UV to determine total protein (Bio-Rad
474 ChemiDoc XR, Image Lab Software). Proteins were transferred to PVDF membranes (Bio-Rad),
475 blocked, then incubated overnight at 4°C with caspase-1 polyclonal (1:1000, #2225), caspase-3
476 polyclonal (1:1000, #9662), caspase-4 polyclonal (1:1000, #4450) or caspase-8 monoclonal
477 (1:1000, #4790) antibodies (Cell Signalling Technology). PVDF membranes were washed thrice
478 between incubations for 5 min with tris-buffered saline containing 0.1% (v/v) Tween 20. PVDF
479 membranes were incubated with horseradish peroxidase-conjugated goatαrabbit IgG (1:5000,
480 Invitrogen) for 1 h at RT and detected using Clarity or Clarity Max Western ECL Blotting Substrate
481 (Bio-Rad) and imaged (Amersham AI600). Bands were quantified using ImageJ software
482 (National Institutes of Health) as area under the peak and normalised over UV determined total
483 protein.

484 **FAM-FLICA caspase-1 activation**

485 Caspase-1 activation was measured using FAM-FLICA Caspase-1 assay kit (ImmunoChemistry
486 Technologies) as per the manufacturer's instructions. In brief, following co-culture of human
487 neutrophils with GAS, cells were removed and incubated in serum free medium (RPMI-1640)
488 containing 1 x FAM-YVAD-FMK for 60 min at 37°C. Cells were then analysed for caspase-1
489 activation via flow cytometry.

490 **Cytometric cytokine bead assay**

491 Human neutrophil supernatants were at indicated times during GAS infection, snap frozen with
492 liquid N_2 and stored at -80°C for a period no longer than 5 days. Neutrophils were assessed for
493 the release of cytokines IL-1β, IL-8, IL-18 and TNF-α using the LEGENDplex™ human
494 inflammation panel bead-based immunoassay (BioLegend) and flow cytometry as per
495 manufacturer's instructions. In brief, samples and standards were incubated with beads and
496 detection antibodies for 120 min at room temperature, with shaking (600 rpm) protected from
497 light. PE-conjugated streptavidin was then added and incubated for a further 30 min at room
498 temperature, with shaking (600 rpm) protected from light. Beads were washed twice with
499 LEGENDplex™ wash buffer and data collected via flow cytometry. Beads were initially gated upon
500 FSC-A and SSC-A (A and B populations). Cytokines have signature APC fluorescence with
501 quantitative expression determined using PE fluorescence in comparison to cytokine standards.
502 Data was analysed using the LEGENDplex™ software V8.0 (VigeneTech Inc.).

503 **Cluster of differentiation expression**

504 Human neutrophil cell surface CD expression was assessed during GAS infection. Neutrophils at
505 indicated times were washed with PBS then routinely incubated with Zombie Aqua Fixable
506 Viability Kit for 15 min at RT. Cells were washed once again in PBS, followed by 10% (v/v) FBS in
507 PBS. Neutrophils were stained with fluorochrome-conjugated antibodies CD11b-FITC (Clone
508 ICRF44), CD31-PE/Cy7 (Clone WM59), or CD66b-PerCP/Cy5.5 (Clone G10F5) (BioLegend) and
509 CD16-FITC (Clone 3G8, Benton Dickson) for 15 min at RT. Neutrophils were washed with 10%
510 (v/v) FBS in PBS then analysed via flow cytometry.

511 **Murine intradermal GAS infection model**

512 Intradermal GAS challenge of C57BL/6J mice has been described previously (Ly et al., 2014,
513 Maamary et al., 2010, Tsatsaronis et al., 2014). In brief, equal numbers of 6-8 week old male and
514 female C57BL/6J mice (Australian BioResources) were anesthetised via isoflurane inhalation,
515 followed by two intradermal injections into shaved left and right flanks with either 1 x 10^8 CFU
516 of mid-logarithmic GAS or 100 μL sterile 0.7% saline. Mice were euthanised via slow-fill CO_2

517 asphyxiation at 6 or 24 h post-infection. Blood collected via cardiac puncture was separated into
518 two aliquots for serum and flow cytometric analysis. Serum was collected by clotting for 1 h at RT
519 then placed on ice until centrifugation at 1200 x *g* for 10 min at 4°C, then immediately stored at -
520 80°C until use. Remaining blood samples were mixed with 20 µL 0.5% sodium citrate (w/v) per
521 mL of blood and placed on ice. Equal volume of PBS was added to the blood sample and
522 centrifuged at 350 x *g* for 5 min. For erythrocyte lysis, samples were incubated with 1 mL of
523 ammonium-chloride-potassium lysing buffer (150 mM NH_4Cl, 1 mM $KHCO_3$, 0.1 mM Na_2CO_3, pH
524 7.3) for 5 min with gentle agitation and centrifuged at 350 x *g* for 5 min. This process was repeated
525 and cells were then washed with PBS and resuspended in 500 µL PBS and placed on ice.
526 Additionally, sites of infection were lavaged with 1 mL of sterile 0.7% saline, and fluid collected
527 from both right and left flanks was pooled to increase cell numbers. Pooled samples were kept
528 cold until centrifugation at 350 x G for 5 min, resuspended in 500 µL of PBS and placed on ice.
529 Both blood and lavage fluid samples were analysed via flow cytometry.

530 **Flow cytometric analysis of murine cells**

531 Cell viability was assessed as described above. To assess caspase-1 activation and CD expression,
532 cells were initially washed with 1 mL of PBS, followed by 1 mL of 10% (v/v) FBS in PBS. Cells
533 were then centrifuged and simultaneously stained with 1 x 660-YVAD-FMK (FLICA 660 Caspase-
534 1 assay kit, ImmunoChemistry Technologies) for caspase-1 activation and with fluorochrome-
535 conjugated antibodies CD45-BV421 (clone 30-F11), CD11b-PE/Cy5 (clone M1-70) and Ly-6G-PE
536 (clone 1A8) (Biolegend) and CD16-FITC (clone AT154-2, Bio-Rad) in RPMI 1640 media for 30 min
537 at RT . Cells were washed with 10% (v/v) FBS in PBS and analysed via flow cytometry.

538 **Murine serum IL-1β concentration**

539 IL-1β release was measured in murine serum using the LEGENDplex™ mouse inflammation panel
540 bead-based immunoassay (BioLegend) and flow cytometry as described above except shaking
541 was performed at 800 rpm.

542 **Statistical analyses**

543 Graphs were created using Prism 6 (GraphPad Software Inc.) and statistical analysis was
544 performed using Prism 6 and IBM SPSS Statistics 25 (IBM® corporation). Data was analysed
545 using one-way and two-way ANOVA to determine significant differences and adjusted using
546 Tukey HSD corrections or as stated otherwise. To account for the nested nature of the human
547 neutrophil Annexin-V/Zombie and CD data with repeated measures over time in the same donor,
548 a linear mixed model was used to determine significant interaction between treatment and time.
549 Post-hoc tests were performed by multiple one-way ANOVA at each time point where multiple
550 comparisons were adjusted using Tukey HSD corrections. *In vivo* data was analysed by two-way
551 ANOVA where differences are shown between treatment and time, also using Tukey HSD
552 corrections. Values presented for 'p' represent interaction (treatment*time) unless otherwise
553 stated. * $p<0.05$; ** $p<0.01$; *** $p<0.001$; **** $p<0.0001$.

554 **References**

555 Arnaout, M. A. 1990. Structure and function of the leukocyte adhesion molecule CD11/CD18. *Blood,*
556 75**,** 1037-1050.
557 Ato, M., Ikebe, T., Kawabata, H., Takemori, T. & Watanabe, H. 2008. Incompetence of neutrophils to
558 invasive group A streptococcus is attributed to induction of plural virulence factors by
559 dysfunction of a regulator. *PLoS ONE,* 3.
560 Aziz, R. K. & Kotb, M. 2008. Rise and persistence of global M1T1 clone of Streptococcus pyogenes.
561 *Emerging Infectious Diseases,* 14**,** 1511-1517.
562 Aziz, R. K., Pabst, M. J., Jeng, A., Kansal, R., Low, D. E., Nizet, V. & Kotb, M. 2004. Invasive M1T1
563 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of
564 multiple virulence factors by SpeB. *Molecular Microbiology,* 51**,** 123-134.
565 Boucher, D., Monteleone, M., Coll, R. C., Chen, K. W., Ross, C. M., Teo, J. L., Gomez, G. A., Holley, C.
566 L., Bierschenk, D., Stacey, K. J., Yap, A. S., Bezbradica, J. S. & Schroder, K. 2018. Caspase-1
567 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. *Journal of*
568 *Experimental Medicine,* 215**,** 827-840.
569 Bratton, D. L. & Henson, P. M. 2011. Neutrophil clearance: When the party is over, clean-up begins.
570 *Trends in Immunology,* 32**,** 350-357.
571 Brown, K., Brain, S., Pearson, J., Edgeworth, J., Lewis, S. & Treacher, D. 2006. Neutrophils in
572 development of multiple organ failure in sepsis. *Lancet,* 368**,** 157-169.
573 Brown, S., Heinisch, I., Ross, E., Shaw, K., Buckley, C. O. & Savill, J. 2002. Apoptosis disables CD31-
574 mediated cell detachment from phagocytes promoting binding and engulfment. *Nature,* 418**,**
575 200-203.
576 Broz, P., Von Moltke, J., Jones, J. W., Vance, R. E. & Monack, D. M. 2010. Differential requirement for
577 caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. *Cell Host*
578 *and Microbe,* 8**,** 471-483.

579 Castiglia, V., Piersigilli, A., Ebner, F., Janos, M., Goldmann, O., Damböck, U., Kröger, A., Weiss, S.,
580 Knapp, S., Jamieson, A. M., Kirschning, C., Kalinke, U., Strobl, B., Müller, M., Stoiber, D.,
581 Lienenklaus, S. & Kovarik, P. 2016. Type i Interferon Signaling Prevents IL-1β-Driven Lethal
582 Systemic Hyperinflammation during Invasive Bacterial Infection of Soft Tissue. *Cell Host and*
583 *Microbe,* 19**,** 375-387.
584 Chatellier, S., Ihendyane, N., Kansal, R. G., Khambaty, F., Basma, H., Norrby-Teglund, A., Low, D. E.,
585 Mcgeer, A. & Kotb, M. 2000. Genetic relatedness and superantigen expression in group A
586 streptococcus serotype M1 isolates from patients with severe and nonsevere invasive
587 diseases. *Infection and Immunity,* 68**,** 3523-3534.
588 Chen, C. J., Kono, H., Golenbock, D., Reed, G., Akira, S. & Rock, K. L. 2007. Identification of a key
589 pathway required for the sterile inflammatory response triggered by dying cells. *Nature*
590 *Medicine,* 13**,** 851-856.
591 Cole, J. N., Barnett, T. C., Nizet, V. & Walker, M. J. 2011. Molecular insight into invasive group A
592 streptococcal disease. *Nature Reviews Microbiology,* 9**,** 724-736.
593 Davies, H. D., Mcgeer, A., Schwartz, B., Green, K., Cann, D., Simor, A. E. & Low, D. E. 1996. Invasive
594 group A streptococcal infections in Ontario, Canada. *New England Journal of Medicine,* 335**,**
595 547-554.
596 Dransfield, I., Buckle, A. M., Savill, J. S., Mcdowall, A., Haslett, C. & Hogg, N. 1994. Neutrophil
597 apoptosis is associated with a reduction in CD16 (FcγRIII) expression. *Journal of Immunology,*
598 153**,** 1254-1263.
599 Edwards, R. J., Pyzio, M., Gierula, M., Turner, C. E., Abdul-Salam, V. B. & Sriskandan, S. 2018.
600 Proteomic analysis at the sites of clinical infection with invasive Streptococcus pyogenes.
601 *Scientific Reports,* 8.
602 Epstein, F. H. & Weiss, S. J. 1989. Tissue Destruction by Neutrophils. *New England Journal of*
603 *Medicine,* 320**,** 365-376.
604 Faurschou, M. & Borregaard, N. 2003. Neutrophil granules and secretory vesicles in inflammation.
605 *Microbes and Infection,* 5**,** 1317-1327.
606 Fiebig, A., Loof, T. G., Babbar, A., Itzek, A., Koehorst, J. J., Schaap, P. J. & Nitsche-Schmitz, D. P. 2015.
607 Comparative Genomics of Streptococcus pyogenes M1 isolates differing in virulence and
608 propensity to cause systemic infection in mice. *International Journal of Medical*
609 *Microbiology,* 305**,** 532-543.
610 Fossati, G., Moots, R. J., Bucknall, R. C. & Edwards, S. W. 2002. Differential role of neutrophil Fcγ
611 receptor IIIb (CD16) in phagocytosis, bacterial killing, and responses to immune complexes.
612 *Arthritis and Rheumatism,* 46**,** 1351-1361.
613 Geering, B. & Simon, H. U. 2011. Peculiarities of cell death mechanisms in neutrophils. *Cell Death*
614 *and Differentiation,* 18**,** 1457-1469.
615 Ghimire, L., Paudel, S., Jin, L., Baral, P., Cai, S. & Jeyaseelan, S. 2018. NLRP6 negatively regulates
616 pulmonary host defense in Gram-positive bacterial infection through modulating neutrophil
617 recruitment and function. *PLoS Pathogens,* 14.
618 Greenlee-Wacker, M. C., Kremserová, S. & Nauseef, W. M. 2017. Lysis of human neutrophils by
619 community-associated methicillin-resistant Staphylococcus aureus. *Blood,* 129**,** 3237-3244.
620 Henningham, A., Döhrmann, S., Nizet, V. & Cole, J. N. 2015. Mechanisms of group A Streptococcus
621 resistance to reactive oxygen species. *FEMS Microbiology Reviews,* 39**,** 488-508.
622 Huston, J. M., Rosas-Ballina, M., Xue, X., Dowling, O., Ochani, K., Ochani, M., Yeboah, M. M.,
623 Chatterjee, P. K., Tracey, K. J. & Metz, C. N. 2009. Cholinergic neural signals to the spleen
624 down-regulate leukocyte trafficking via CD11b. *Journal of Immunology,* 183**,** 552-559.
625 Kilsgård, O., Karlsson, C., Malmström, E. & Malmström, J. 2016. Differential compartmentalization of
626 Streptococcus pyogenes virulence factors and host protein binding properties as a
627 mechanism for host adaptation. *International Journal of Medical Microbiology*.
628 Kipnis, E. 2013. Neutrophils in sepsis: Battle of the bands. *Critical Care Medicine,* 41**,** 925-926.

629 Kobayashi, S. D., Braughton, K. R., Whitney, A. R., Voyich, J. M., Schwan, T. G., Musser, J. M. & Deleo,
630 F. R. 2003. Bacterial pathogens modulate an apoptosis differentiation program in human
631 neutrophils. *Proceedings of the National Academy of Sciences of the United States of*
632 *America,* 100**,** 10948-10953.
633 Kobayashi, S. D., Malachowa, N. & Deleo, F. R. 2018. Neutrophils and Bacterial Immune Evasion.
634 *Journal of Innate Immunity,* 10**,** 432-441.
635 Kovach, M. A. & Standiford, T. J. 2012. The function of neutrophils in sepsis. *Current Opinion in*
636 *Infectious Diseases,* 25**,** 321-327.
637 Kurosaka, K., Takahashi, M., Watanabe, N. & Kobayashi, Y. 2003. Silent Cleanup of Very Early
638 Apoptotic Cells by Macrophages. *Journal of Immunology,* 171**,** 4672-4679.
639 Lamagni, T. L., Darenberg, J., Luca-Harari, B., Siljander, T., Efstratiou, A., Henriques-Normark, B.,
640 Vuopio-Varkila, J., Bouvet, A., Creti, R., Ekelund, K., Koliou, M., Reinert, R. R., Stathi, A.,
641 Strakova, L., Ungureanu, V., Schalén, C., Jasir, A., Ioannou, Y., Kriz, P., Motlova, J.,
642 Hammerum, A., Kaltoft, M. S., Iivonen, J., Loubinoux, J., Mihaila, L., Van Der Linden, M.,
643 Lütticken, R., Papaparaskevas, J., Zachariadou, L., Baldassarri, L., Orefici, G., Straut, M.,
644 Norrby-Teglund, A., Keshishian, C. & Neal, S. 2008. Epidemiology of severe Streptococcus
645 pyogenes disease in Europe. *Journal of Clinical Microbiology,* 46**,** 2359-2367.
646 Larock, C. N. & Nizet, V. 2015. Inflammasome/IL-1β responses to streptococcal pathogens. *Frontiers*
647 *in Immunology,* 6.
648 Lioy, V. S., Pratto, F., De La Hoz, A. B., Ayora, S. & Alonso, J. C. 2010. Plasmid pSM19035, a model to
649 study stable maintenance in Firmicutes. *Plasmid,* 64**,** 1-17.
650 Loh, J. M. S. & Proft, T. 2013. Toxin-antitoxin-stabilized reporter plasmids for biophotonic imaging of
651 Group A streptococcus. *Applied Microbiology and Biotechnology,* 97**,** 9737-9745.
652 Lundqvist-Gustafsson, H. & Bengtsson, T. 1999. Activation of the granule pool of the NADPH oxidase
653 accelerates apoptosis in human neutrophils. *Journal of Leukocyte Biology,* 65**,** 196-204.
654 Ly, D., Taylor, J. M., Tsatsaronis, J. A., Monteleone, M. M., Skora, A. S., Donald, C. A., Maddocks, T.,
655 Nizet, V., West, N. P., Ranson, M., Walker, M. J., Mcarthur, J. D. & Sanderson-Smith, M. L.
656 2014. Plasmin(ogen) Acquisition by Group A Streptococcus Protects against C3b-Mediated
657 Neutrophil Killing. *Journal of Innate Immunity,* 6**,** 240-250.
658 Maamary, P. G., Sanderson-Smith, M. L., Aziz, R. K., Hollands, A., Cole, J. N., Mckay, F. C., Mcarthur, J.
659 D., Kirk, J. K., Cork, A. J., Keefe, R. J., Kansal, R. G., Sun, H., Taylor, W. L., Chhatwal, G. S.,
660 Ginsburg, D., Nizet, V., Kotb, M. & Walker, M. J. 2010. Parameters governing invasive disease
661 propensity of non-M1 serotype group A Streptococci. *Journal of Innate Immunity,* 2**,** 596-
662 606.
663 Man, S. M. & Kanneganti, T. D. 2016. Converging roles of caspases in inflammasome activation, cell
664 death and innate immunity. *Nature Reviews Immunology,* 16**,** 7-21.
665 Mclaughlin, R. E. & Ferretti, J. J. 1995. Electrotransformation of Streptococci. *Methods in Molecular*
666 *Biology (Clifton, N.J.),* 47**,** 185-193.
667 Medina, E., Goldmann, O., Toppel, A. W. & Chhatwal, G. S. 2003a. Survival of Streptococcus
668 pyogenes within host phagocytic cells: A pathogenic mechanism for persistence and
669 systemic invasion. *Journal of Infectious Diseases,* 187**,** 597-603.
670 Medina, E., Rohde, M. & Chhatwal, G. S. 2003b. Intracellular survival of Streptococcus pyogenes in
671 polymorphonuclear cells results in increased bacterial virulence. *Infection and Immunity,* 71**,**
672 5376-5380.
673 Nelson, G. E., Pondo, T., Toews, K. A., Farley, M. M., Lindegren, M. L., Lynfield, R., Aragon, D., Zansky,
674 S. M., Watt, J. P., Cieslak, P. R., Angeles, K., Harrison, L. H., Petit, S., Beall, B. & Van Beneden,
675 C. A. 2016. Epidemiology of invasive group a streptococcal infections in the United States,
676 2005-2012. *Clinical Infectious Diseases,* 63**,** 478-486.
677 Nguyen, G. T., Green, E. R. & Mecsas, J. 2017. Neutrophils to the ROScue: Mechanisms of NADPH
678 oxidase activation and bacterial resistance. *Frontiers in Cellular and Infection Microbiology,*
679 7.

680 Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y.,
681 Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin,
682 T. T., Yu, V. L. & Miller, D. K. 1995. Identification and inhibition of the ICE/CED-3 protease
683 necessary for mammalian apoptosis. *Nature,* 376**,** 37-43.
684 Norrby-Teglund, A., Chatellier, S., Low, D. E., Mcgeer, A., Green, K. & Kotb, M. 2000. Host variation in
685 cytokine responses to superantigens determine the severity of invasive group A
686 streptococcal infection. *European Journal of Immunology,* 30**,** 3247-3255.
687 O'grady, K. a. F., Kelpie, L., Andrews, R. M., Curtis, N., Nolan, T. M., Selvaraj, G., Passmore, J. W.,
688 Oppedisano, F., Carnie, J. A. & Carapetis, J. R. 2007. The epidemiology of invasive group A
689 streptococcal disease in Victoria, Australia. *Medical Journal of Australia,* 186**,** 565-569.
690 O'loughlin, R. E., Roberson, A., Cieslak, P. R., Lynfield, R., Gershman, K., Craig, A., Albanese, B. A.,
691 Farley, M. M., Barrett, N. L., Spina, N. L., Beall, B., Harrison, L. H., Reingold, A. & Van
692 Beneden, C. 2007. The epidemiology of invasive group A streptococcal infection and
693 potential vaccine implications: United States, 2000-2004. *Clinical Infectious Diseases,* 45**,**
694 853-862.
695 O'neill, A. M., Thurston, T. L. M. & Holden, D. W. 2016. Cytosolic replication of group a Streptococcus
696 in human macrophages. *mBio,* 7.
697 Power, C., Wang, J. H., Sookhai, S., Wu, Q. D. & Redmond, H. P. 2001. Proinflammatory effects of
698 bacterial lipoprotein on human neutrophil activation status, function and cytotoxic potential
699 in vitro. *Shock,* 15**,** 461-466.
700 Ryu, J. C., Kim, M. J., Kwon, Y., Oh, J. H., Yoon, S. S., Shin, S. J., Yoon, J. H. & Ryu, J. H. 2017.
701 Neutrophil pyroptosis mediates pathology of P. aeruginosa lung infection in the absence of
702 the NADPH oxidase NOX2. *Mucosal Immunology,* 10**,** 757-774.
703 Schneider, K. S., Groß, C. J., Dreier, R. F., Saller, B. S., Mishra, R., Gorka, O., Heilig, R., Meunier, E.,
704 Dick, M. S., Ćiković, T., Sodenkamp, J., Médard, G., Naumann, R., Ruland, J., Kuster, B., Broz,
705 P. & Groß, O. 2017. The Inflammasome Drives GSDMD-Independent Secondary Pyroptosis
706 and IL-1 Release in the Absence of Caspase-1 Protease Activity. *Cell Reports,* 21**,** 3846-3859.
707 Skubitz, K. M., Campbell, K. D. & Skubitz, A. P. N. 1996. CD66a, CD66b, CD66c, and CD66d each
708 independently stimulate neutrophils. *Journal of Leukocyte Biology,* 60**,** 106-117.
709 Sollberger, G., Strittmatter, G. E., Kistowska, M., French, L. E. & Beer, H. D. 2012. Caspase-4 is
710 required for activation of inflammasomes. *Journal of Immunology,* 188**,** 1992-2000.
711 Sumby, P., Porcella, S. F., Madrigal, A. G., Barbian, K. D., Virtaneva, K., Ricklefs, S. M., Sturdevant, D.
712 E., Graham, M. R., Vuopio-Varkila, J., Hoe, N. P. & Musser, J. M. 2005. Evolutionary origin
713 and emergence of a highly successful clone of serotype M1 group A Streptococcus involved
714 multiple horizontal gene transfer events. *Journal of Infectious Diseases,* 192**,** 771-782.
715 Sumby, P., Whitney, A. R., Graviss, E. A., Deleo, F. R. & Musser, J. M. 2006. Genome-wide analysis of
716 group A streptococci reveals a mutation that modulates global phenotype and disease
717 specificity. *PLoS Pathogens,* 2**,** 0041-0049.
718 Svensson, N., Öberg, S., Henriques, B., Holm, S., Källenius, G., Romanus, V. & Giesecke, J. 2000.
719 Invasive group A streptococcal infections in Sweden in 1994 and 1995: Epidemiology and
720 clinical spectrum. *Scandinavian Journal of Infectious Diseases,* 32**,** 609-614.
721 Tart, A. H., Walker, M. J. & Musser, J. M. 2007. New understanding of the group A Streptococcus
722 pathogenesis cycle. *Trends in Microbiology,* 15**,** 318-325.
723 Tecchio, C., Micheletti, A. & Cassatella, M. A. 2014. Neutrophil-derived cytokines: Facts beyond
724 expression. *Frontiers in Immunology,* 5.
725 Tran, T. a. T., Grievink, H. W., Lipinska, K., Kluft, C., Burggraaf, J., Moerland, M., Tasev, D. & Malone,
726 K. E. 2019. Whole blood assay as a model for in vitro evaluation of inflammasome activation
727 and subsequent caspase-mediated interleukin-1 beta release. *PLoS ONE,* 14.
728 Tsatsaronis, J. A., Ly, D., Pupovac, A., Goldmann, O., Rohde, M., Taylor, J. M., Walker, M. J., Medina,
729 E. & Sanderson-Smith, M. L. 2015. Group A Streptococcus Modulates Host Inflammation by

730 Manipulating Polymorphonuclear Leukocyte Cell Death Responses. *Journal of Innate*
731 *Immunity,* 7**,** 612-622.
732 Tsatsaronis, J. A., Walker, M. J. & Sanderson-Smith, M. L. 2014. Host Responses to Group A
733 Streptococcus: Cell Death and Inflammation. *PLoS Pathogens,* 10.
734 Valderrama, J. A., Riestra, A. M., Gao, N. J., Larock, C. N., Gupta, N., Ali, S. R., Hoffman, H. M., Ghosh,
735 P. & Nizet, V. 2017. Group A streptococcal M protein activates the NLRP3 inflammasome.
736 *Nature Microbiology,* 2**,** 1425-1434.
737 Walker, M. J., Hollands, A., Sanderson-Smith, M. L., Cole, J. N., Kirk, J. K., Henningham, A., Mcarthur,
738 J. D., Dinkla, K., Aziz, R. K., Kansal, R. G., Simpson, A. J., Buchanan, J. T., Chhatwal, G. S., Kotb,
739 M. & Nizet, V. 2007. DNase Sda1 provides selection pressure for a switch to invasive group A
740 streptococcal infection. *Nature Medicine,* 13**,** 981-985.
741 Wang, Q., Imamura, R., Motani, K., Kushiyama, H., Nagata, S. & Suda, T. 2013. Pyroptotic cells
742 externalize eat-me and release find-me signals and are efficiently engulfed by macrophages.
743 *International Immunology,* 25**,** 363-372.
744 Wierzbicki, I. H., Campeau, A., Dehaini, D., Holay, M., Wei, X., Greene, T., Ying, M., Sands, J. S.,
745 Lamsa, A., Zuniga, E., Pogliano, K., Fang, R. H., Larock, C. N., Zhang, L. & Gonzalez, D. J. 2019.
746 Group A Streptococcal S Protein Utilizes Red Blood Cells as Immune Camouflage and Is a
747 Critical Determinant for Immune Evasion. *Cell Reports*.

748

Supplemental Information



Supplementary figure 1. The association of fluorescent GAS (GFP) to human neutrophils determined via flow cytometry. (A) Primary neutrophil (PMN) 'Singlets' cell selection (FSC-A vs. FSC-H) and (B) viable 'PMNs' discrimination (FSC-A vs. SSC-A). (C) Representative histogram showing relative fluorescence (GFP) of GAS infected neutrophils and gating for the selection of GAS-neutrophil association. (D) Rate of ROS production by neutrophils between 30-60 min (n=6 donors). (E) GAS killing by human neutrophils is inhibited at 30 min following pre-incubation with actin polymerising molecule cytochalasin D (n=4 donors, Sidak's multiple comparison). Results are the pooled means±SD (of triplicate measurements for panels D and E). **p<0.01, ***p<0.001.



Supplementary figure 2. Quantification of protein bands in human neutrophil lysates identified through immunoblotting. (A) Caspase-3 p17, (B) caspase-1 full-length, (D) caspase-1 p46 and (D) caspase-4 immunoblots were imaged then analysed using ImageJ where area under the curve was normalised over total protein. Results are the means±SD where 3 donors were used. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, with black asterisks denoting significance to control and grey asterisks between 5448 and 5448AP.



767 **Supplementary figure 3. Human neutrophils were assessed for the activation of caspase-1**
768 **and release of cytokines via and flow cytometry.** (A) Primary neutrophil (PMN) 'Singlet' cell
769 selection (FSC-A vs. FSC-H) and (B) viable 'PMNs' discrimination (FSC-A vs. SSC-A). (C)
770 Representative plot showing unstained and GAS infected neutrophils (Singlets/PMNs) with
771 FLICA (FAM-YVAD-FMK) fluorescence. Gating strategy for LEGENDplex cytometric bead assay
772 where (D) beads A and B were gated (FSC-A vs. SSC-A). Gates for beads A (shown) and B were
773 assessed for (E) PE vs. APC fluorescence where cytokines had unique APC fluorescence and
774 expression was measured via PE fluorescence when compared to a standard curve.

775



Supplementary figure 4. Flow cytometric sequential gating strategy for identification of murine neutrophils determining caspase-1 activation. (A) Primary 'Singlets' cell selection (FSC-A vs. FSC-H) and (B) 'Cells' discrimination (FSC-A vs. SSC-A) of murine blood and lavage fluid. 'Cells' were further gated upon (C) CD45-BV421 expression and (D) CD11b-PE/Cy5 expression. Neutrophils (PMNS) were defined as (E) Ly-6G-PE$_+$ cells from the CD45$_+$/CD11b$_+$ population. Neutrophils were assessed for (F) caspase-1 activation using FLICA 660 (660-YVAD-FMK).